A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk

Acta Oncologica

Volumn 49, Issue 6, 2010, Pages 767-775

  Andersson, Ulrika ^a   Schwartzbaum, Judith ^b   Wiklund, Fredrik ^c   Sjöström, Sara ^a   Liu, Yanhong ^d   Tsavachidis, Spyros ^d   Ahlbom, Anders ^c   Auvinen, Anssi ^e,f   Collatz Laier, Helle ^g   Feychting, Maria ^c   Johansen, Christoffer ^g   Kiuru, Anne ^f   Lnn, Stefan ^c   Schoemaker, Minouk J ^h   Swerdlow, Anthony J ^h   Henriksson, Roger ^a   Bondy, Melissa ^d   Melin, Beatrice ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Department of Computational Medicine and Bioinformatics School of Public Health   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TAMPERE   (Finland)

^f STUK RADIATION AND NUCLEAR SAFETY AUTHORITY   (Finland)

^g INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLIOBLASTOMA; GLIOMA; HAPLOTYPE; HUMAN; INTRON; LRIG2 GENE; LRIG3 GENE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; DENMARK; ENGLAND; FEMALE; FINLAND; GENOTYPE; GLIOMA; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; SWEDEN;

EID: 77954513404     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.480980     Document Type: Article

References (35)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996
2. Malmer B, Iselius L, Holmberg E, Collins A, Henriksson R, Grönberg H. Genetic epidemiology of glioma. Br J Cancer 2001;84:429-434
3. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008;40:631-637
4. Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, et al. Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:702-705
5. Malmer BS, Feychting M, Lönn S, Lindström S, Grönberg H, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol 2007;82:229-237
6. Bethke L, Webb E, Murray A, Schoemaker M, Johansen C, Christensen HC, et al. Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Hum Mol Genet 2008;17:800-805 (Pubitemid 351359696)
7. Rajaraman P, Hutchinson A, Rothman N, Black PM, Fine HA, Loeffl er JS, et al. Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol 2008.
8. Chang JS, Yeh RF, Wiencke JK, Wiemels JL, Smirnov I, Pico AR, et al. Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev 2008;17:1368-1373
9. Collins VP. Mechanisms of disease: Genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 2007;4:362-374
10. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-7731
11. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-1453
12. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. Embo J 2004;23:3270-3281
13. Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling-double-edged swords in human cancer? Eur J Cancer 2007;43:676-682
14. Johansson M, Brännström T, Bergenheim AT, Henriksson R. Spatial expression of VEGF-A in human glioma. J Neurooncol 2002;59:1-6.
15. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3 ' -kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-5886
16. Schwartzbaum JA, Ahlbom A, Lönn S, Warholm M, Rannug A, Auvinen A, et al. An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol Biomarkers Prev 2007;16:559-565
17. Cardis E, Richardson L, Deltour I, Armstrong B, Feychting M, Johansen C, et al. The INTERPHONE study: Design, epidemiological methods, and description of the study population. Eur J Epidemiol 2007;22:647-664
18. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009;41: 899-904.
19. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-874
20. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-649
21. Buerger H, Gebhardt F, Schmidt H, Beckmann A, Hutmacher K, Simon R, et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 2000;60:854-857
22. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: An approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-442
23. Kraft P. Effi cient two-stage genome-wide association designs based on false positive report probabilities. Pac Symp Biocomput 2006:523-534
24. Hoh J, Hodge SE. A measure of phase ambiguity in pairs of SNPs in the presence of linkage disequilibrium. Hum Hered 2000;50:359-364
25. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005;65:46-53.
26. Buerger H, Packeisen J, Boecker A, Tidow N, Kersting C, Bielawski K, et al. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifi cations of this sequence-fi rst results of an inter-ethnic breast cancer study. J Pathol 2004;203:545-550
27. Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, et al. Relationship of EGFR mutations, expression, amplifi cation, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 2007;13(22 Pt 1):6788-6795
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265
29. Stutz MA, Shattuck DL, Laederich MB, Carraway KL 3rd, Sweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008;27:5741-5752
30. Ohgaki H, Kita D, Favereaux A, Huang H, Homma T, Dessen P, et al. Brain tumors in S100beta-v-erbB transgenic rats. J Neuropathol Exp Neurol 2006;65:1111-1117
31. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, et al. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 2003;63: 1589-1595
32. Carpentier C, Laigle-Donadey F, Marie Y, Auger N, Benouaich- Amiel A, Lejeune J, et al. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology 2006;67:872-874
33. Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H, et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 2004;108:135-142
34. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-1068
35. Yu H, Gong X, Luo X, Han W, Hong G, Singh B, et al. Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways. Cancer Biol Ther 2008;7.